Leqembi® Projected to Drive ¥300 Billion Sales, Boosting Eisai’s FY 2028 Growth
Projected Leqembi sales hit ¥300 billion in FY 2029, showing strong growth for Eisai’s Alzheimer’s therapy and boosting its market value.
2 minutes to read
Eisai Co Ltd
Leqembi® Forecasts ¥143.5 Billion Revenue in FY2026, 63% Growth for Eisai
Projected Leqembi® revenue for FY 2026 hits ¥143.5 billion—Eisai’s strongest Alzheimer’s drug growth, driven by a 63 % jump and BioArctic royalty partnership.
3 minutes to read
China Grants Regulatory Acceptance for Eisai’s Subcutaneous Leqembi – A Key Milestone in Alzheimer’s Treatment
Read how Eisai’s subcutaneous Leqembi gained Chinese regulatory acceptance, unlocking a new Alzheimer’s market and boosting its portfolio.
2 minutes to read
Eisai Faces Stock Decline Amid Anticipation for Upcoming Financial Report and Strong Leqembi Revenue Projections
Eisai Co., Ltd. is preparing to release its financial report, with analysts projecting a decline in earnings per share, but the company is also expecting robust revenue from its Alzheimer’s treatment, Leqembi.
2 minutes to read